AF488 Anti-Human CD47 Antibody[CC2C6D4]

Introducing the AF488 Anti-Human CD47 Antibody [CC2C6D4], a cutting-edge product designed to revolutionize the field of immunology. This antibody, labeled with AF488, offers exceptional specificity and sensitivity in detecting CD47, a transmembrane protein highly expressed on the surface of human cells.

Crafted with meticulous precision, this antibody exhibits remarkable binding affinity towards CD47, enabling accurate identification and characterization of this crucial protein. Its AF488 label further enhances its utility by providing a fluorescent signal, facilitating easy visualization and quantification of CD47 expression in various experimental settings.

The AF488 Anti-Human CD47 Antibody [CC2C6D4] has been rigorously validated through extensive testing, ensuring its reliability and reproducibility. Its exceptional performance in immunofluorescence, flow cytometry, and immunohistochemistry techniques makes it an indispensable tool for researchers and clinicians alike.

This antibody's versatility extends beyond its exceptional performance. It is compatible with a wide range of sample types, including cell lines, primary cells, and tissue sections, enabling comprehensive investigations into CD47 expression across diverse biological systems. Its robustness and stability guarantee consistent results, even in challenging experimental conditions.

Furthermore, the AF488 Anti-Human CD47 Antibody [CC2C6D4] is manufactured under stringent quality control measures, adhering to the highest industry standards. Its formulation ensures long-term stability, allowing for extended shelf life and reliable performance throughout its usage.

In summary, the AF488 Anti-Human CD47 Antibody [CC2C6D4] represents a breakthrough in immunological research, offering unparalleled specificity, sensitivity, and versatility. With its exceptional performance and reliability, this antibody is poised to revolutionize the study of CD47 and contribute to advancements in various fields, including cancer research, immunotherapy, and autoimmune diseases.